Chidamide and azacitidine after transplant for leukemia with minimal residual disease
Tests chidamide with azacitidine in adults with leukemia after stem cell transplant.
Plain-language title generated from the registry record
Registry title: A Study of Chidamide With AZA in MRD Positive AML After Transplant
Key facts
- Where
- Guangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with acute myeloid leukemia (AML) who had a stem cell transplant and still have tiny traces of leukemia (MRD positive).
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- AML (not the M3 type) with MRD positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT)
- Earlier treatment
- Must have had an allogeneic stem cell transplant (allo-HSCT)
- Biomarker or test result
- Small residual disease (MRD) must be positive after the transplant
Main reasons for not taking part
- Allergy to the study drug
- Active infection
- HIV infection, HBV or HCV
- Other cancers
- Pregnant or breastfeeding women
Read by machine on 12 November 2026.
Where in China
- Guangdong Provincial People's HospitalGuangzhou, ChinaContact: WENG jian yu, M.D.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Guangdong Provincial People's Hospital
- Trial code
- NCT06066905
- Record updated
- 27 October 2023
- Original description
acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.Read full original descriptionShow less
A Study of Chidamide With AZA in MRD Positive AML After Transplant
acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.
Inclusion: Patients diagnosed with AML (diagnostic criteria refer to WHO2016 criteria, except M3) can detect small residual lesions (MRD) positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT); ≥18 years old; ECOG≤3; lifespan≥3 months; Take contraceptive measures; Sign informed consent.
Exclusion: Allergic to the study drug; A gastrointestinal condition that prevents oral medication; active infection; other malignancies; HIV infection; HBV or HCV; The QT interval is prolonged; Dysfunction of vital organs; Pregnant or lactating women; Is participating in other clinical studies; The researchers did not consider it appropriate to participate in this study.